CRP and rheumatoid arthritis: The decrease in inflammation (estimated by the CRP level) reached by therapies of RA with abatacept or adalimumab improvement in inflammation and disease activity, correlated with improvement of antioxidant HDL functions and alterations of HDL proteome (LBP, SAA-I, Hp, PON1 activity) [421].